The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 53 | — | 20.1x | Near average | |
Growth | 31 | — | 5.6% | Below average | |
Quality | 17 | -37.9% | 7.6% | Below average | |
Safety | 75 | 0.2x | 0.4x | Above average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Design Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Design Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
DSGN stock has witnessed a notable positive shift in analyst estimates over the past 30 days, with the average price target rising by 17.14% to reach $20.5 compared to a previous $17.5. This increase is primarily attributed to the rise in the number of analysts covering the stock from one to three, with institutions such as Cantor Fitzgerald joining with an 'Overweight' rating, which reduced previous uncertainty and bolstered confidence in the stock's future trajectory.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.